Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib: Case report and literature review

Ehab Saad aldin, Fadi Mourad, Arafat Tfayli

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Imatinib mesylate is a receptor kinase inhibitor approved by the Food and Drug Administration for the treatment of malignant metastatic and/or unresectable gastrointestinal stromal tumors and chronic myelogenous leukemia. Although imatinib is generally well tolerated, certain adverse drug reactions are common. These include gastrointestinal side-effects such as diarrhea, nausea and vomiting, as well as hematological side-effects and other miscellaneous side-effects such as fatigue, edema, dermatitis and dyspnea. We present a previously unreported adverse effect of imatinib, gastric antral vascular ectasia, in a 74-year-old woman with gastrointestinal stromal tumor in remission treated with adjuvant imatinib. Endoscopy performed prior to starting imatinib showed normal gastric mucosa, but 8 months after starting imatinib showed diffuse gastric inflammation. Repeat endoscopy 1 month after discontinuing imatinib showed significant improvement in gastric inflammation.

Original languageEnglish (US)
Article numberhys032
Pages (from-to)447-450
Number of pages4
JournalJapanese Journal of Clinical Oncology
Volume42
Issue number5
DOIs
StatePublished - May 2012
Externally publishedYes

Keywords

  • Gastric antral vascular ectasia
  • Gastrointestinal hemorrhage
  • Gastrointestinal stromal tumors
  • Imatinib
  • Watermelon stomach

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib: Case report and literature review'. Together they form a unique fingerprint.

Cite this